articleThe LancetMar 1, 2025Closed access

Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials

Ghent University · Université de Montréal · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

62
total citations
FWCI
81.51
Percentile
100%
References
31
Citations per year

Authors

18

Topics & keywords

Keywords
  • Chronic rhinosinusitis
  • Nasal polyps
  • Medicine
  • Double blind
  • Internal medicine
  • Surgery
  • Placebo
  • Alternative medicine
No related works found for this paper.

Funding